ABPI sets out strategic imperatives for three-year work program as "VITA"

After a nine-month fundamental review of its operations, the Association of the British Pharmaceutical Industry has announced a three-year work  program based on four strategic imperatives - Value, Innovation, Trust  and Access, which produce the acronym VITA, which is Latin for life,  that will drive and be accountable for the trade group's proactive  campaigns.

Explaining the VITA objectives to a select group pharmaceutical  industry journalists, were the ABPI's president Chris Brinsmead (also  chairman of AstraZeneca Pharmaceuticals UK), the association's director  general Richard Barker and two other executives - David Fisher and Andy  Powrie-Smith, who noted that the sector is facing both opportunities and  challenges.

They pointed out that these four imperatives cannot be viewed  independently. There will be a strong connection with Trust, in terms of  ways of working in partneship and Innovation, where Access to innovative  medicines, diagnostics and therapies will be closely intertwined with  local relationships, both with and across the UK regions and devolved  nations. Value and Access will create messages and positions that the  Trust imperative will explore in its "great medicines debate" with  stakeholders.